Impact of lipodystrophy on the quality of life of HIV-1-infected patients

被引:58
作者
Blanch, J [1 ]
Rousaud, A [1 ]
Martínez, E [1 ]
De Lazzari, E [1 ]
Peri, JM [1 ]
Milinkovic, A [1 ]
Perez-Cuevas, TB [1 ]
Blanco, TL [1 ]
Gatell, JM [1 ]
机构
[1] Hosp Clin Univ Barcelona, Clin Inst Psychiat & Psychol, Barcelona 08036, Spain
关键词
antiretroviral therapy; lipodystrophy; psychosocial; quality of life;
D O I
10.1097/00126334-200212010-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Lipodystrophy (LD) represents an important problem for HIV-1-infected patients receiving highly active antiretroviral therapy (HAART), although its impact on quality of life (QoL) has not been properly studied. Design: Cross-sectional, nonrandomized, observational study performed on consecutive, clinically stable outpatients taking HAART for more than I year. Methods: Data on patients' characteristics, HIV-1 infection, treatment adherence and adverse effects, overall QoL measured by the Profil der Lebensqualitat Chronis-chkranker (PLC), and the presence of LD defined by clinical criteria were assessed. Results: Eighty-four (56%) of 150 interviewed patients fulfilled criteria for LD. Patients with LD were older, had been taking antiretroviral treatment longer, and reported a poorer physical status than patients without LD. Surprisingly, LD itself was not found to influence overall QoL. However, homosexual patients, unemployed patients, and those patients undergoing current psychiatric treatment showed greater impairment on some of the QoL subscales related to psychological well-being if they suffered from LD. Conclusion: The impact of HIV-related LD on QoL depends on certain patient characteristics, rather than on the presence of LD itself.
引用
收藏
页码:404 / 407
页数:4
相关论文
共 14 条
[1]   Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].
Carr, A ;
Samaras, K ;
Thorisdottir, A ;
Kaufmann, GR ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1999, 353 (9170) :2093-2099
[2]  
COLINS E, 2000, AIDS READ, V10, P546
[3]   The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men [J].
Dukers, NHTM ;
Stolte, IG ;
Albrecht, N ;
Coutinho, RA ;
de Wit, JBF .
AIDS, 2001, 15 (06) :812-813
[4]  
FernandezLopez JA, 1997, MED CLIN-BARCELONA, V109, P245
[5]   Lipodystrophy syndrome in patients with HIV infection -: Quality of life issues [J].
Martínez, E ;
Garcia-Viejo, MA ;
Blanch, J ;
Gatell, JM .
DRUG SAFETY, 2001, 24 (03) :157-166
[6]   Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors:: a prospective cohort study [J].
Martinez, E ;
Mocroft, A ;
García-Viejo, MA ;
Pérez-Cuevas, JB ;
Blanco, JL ;
Mallolas, J ;
Bianchi, L ;
Conget, I ;
Blanch, J ;
Phillips, A ;
Gatell, JM .
LANCET, 2001, 357 (9256) :592-598
[7]  
Mauss S, 2000, AIDS, V14, pS197
[8]  
Mercié P, 1999, LANCET, V354, P867, DOI 10.1016/S0140-6736(05)75937-7
[9]   Fat distribution and metabolic changes in patients with HIV infection [J].
Safrin, S ;
Grunfeld, C .
AIDS, 1999, 13 (18) :2493-2505
[10]   Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment [J].
Schrooten, W ;
Colebunders, R ;
Youle, M ;
Molenberghs, G ;
Dedes, N ;
Koitz, G ;
Finazzi, R ;
de Mey, I ;
Florence, E ;
Dreezen, C .
AIDS, 2001, 15 (08) :1019-1023